• Molecular NameAmosulalol
  • SynonymNA
  • Weight380.465
  • Drugbank_IDN/A
  • ACS_NO85320-68-9
  • Show 3D model
  • LogP (experiment)0.82
  • LogP (predicted, AB/LogP v2.0)0.94
  • pka7.72; 10.04
  • LogD (pH=7, predicted)0.39
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.41
  • LogSw (predicted, AB/LogsW2.0)1.84
  • Sw (mg/ml) (predicted, ACD/Labs)1.59
  • No.of HBond Donors4
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds9
  • TPSA119.26
  • StatusDiscontinued
  • AdministrationN/A
  • PharmacologyA beta blocker.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding97.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAmosulalol is metabolised to at least six metabolites (free and conjugated forms), the main metabolite in humans being the sulfate conjugate of 5-hydroxyl amosulalol.
  • Half life2.8 h (intravenous administration) or 5.7 h (oral)
  • Excretion25 to 35% of an administered dose is excreted in urine unchanged within the first 6 h.
  • Urinary ExcretionN/A
  • CleranceApprox. 8.09 L/h (intravenous); 7.28 L/h (oral).
  • ToxicityToxic by subcutaneous and intravenous routes.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A